Boundless Bio Files S-1 Registration Statement for Proposed Public Offering

Ticker: BOLD · Form: S-1 · Filed: Mar 6, 2024 · CIK: 1782303

Boundless Bio, INC. S-1 Filing Summary
FieldDetail
CompanyBoundless Bio, INC. (BOLD)
Form TypeS-1
Filed DateMar 6, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$252.1 million
Sentimentneutral

Sentiment: neutral

Topics: IPO, S-1 Filing, SEC, Biotechnology, Registration Statement

TL;DR

<b>Boundless Bio, Inc. has filed an S-1 registration statement for a proposed public offering, signaling its intent to become a publicly traded company.</b>

AI Summary

Boundless Bio, Inc. (BOLD) filed a IPO Registration (S-1) with the SEC on March 6, 2024. Boundless Bio, Inc. has filed an S-1 registration statement with the SEC on March 6, 2024. The filing indicates the company is a non-accelerated filer, smaller reporting company, and emerging growth company. The principal executive offices are located at 9880 Campus Point Drive, Suite 120, San Diego, CA 92121. The company's telephone number is (858) 766-9912. The filing is made under the Securities Act of 1933, with registration number 333-277696.

Why It Matters

For investors and stakeholders tracking Boundless Bio, Inc., this filing contains several important signals. This S-1 filing is a crucial step for Boundless Bio, Inc. as it prepares to access public capital markets through an Initial Public Offering (IPO). The classification as an emerging growth company suggests potential benefits regarding regulatory disclosures and compliance requirements compared to larger, more established companies.

Risk Assessment

Risk Level: low — Boundless Bio, Inc. shows low risk based on this filing. The risk is currently low as this is a preliminary filing and no specific financial or operational details of the offering have been disclosed yet.

Analyst Insight

Monitor future filings for details on the offering size, price range, and use of proceeds to assess investment potential.

Key Numbers

Key Players & Entities

FAQ

When did Boundless Bio, Inc. file this S-1?

Boundless Bio, Inc. filed this IPO Registration (S-1) with the SEC on March 6, 2024.

What is a S-1 filing?

A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by Boundless Bio, Inc. (BOLD).

Where can I read the original S-1 filing from Boundless Bio, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Boundless Bio, Inc..

What are the key takeaways from Boundless Bio, Inc.'s S-1?

Boundless Bio, Inc. filed this S-1 on March 6, 2024. Key takeaways: Boundless Bio, Inc. has filed an S-1 registration statement with the SEC on March 6, 2024.. The filing indicates the company is a non-accelerated filer, smaller reporting company, and emerging growth company.. The principal executive offices are located at 9880 Campus Point Drive, Suite 120, San Diego, CA 92121..

Is Boundless Bio, Inc. a risky investment based on this filing?

Based on this S-1, Boundless Bio, Inc. presents a relatively low-risk profile. The risk is currently low as this is a preliminary filing and no specific financial or operational details of the offering have been disclosed yet.

What should investors do after reading Boundless Bio, Inc.'s S-1?

Monitor future filings for details on the offering size, price range, and use of proceeds to assess investment potential. The overall sentiment from this filing is neutral.

How does Boundless Bio, Inc. compare to its industry peers?

Boundless Bio operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.

Are there regulatory concerns for Boundless Bio, Inc.?

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

Risk Factors

Industry Context

Boundless Bio operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

  1. Review the full S-1 filing for detailed business description, risk factors, and financial information.
  2. Track subsequent SEC filings (e.g., amendments to S-1, prospectuses) for offering specifics.
  3. Analyze the company's target market and competitive landscape once more information is available.

Key Dates

Year-Over-Year Comparison

This is the initial S-1 filing, so no prior filing data is available for comparison.

Filing Stats: 4,461 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2024-03-06 16:06:52

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 77 Market and Industry Data 78

Use of Proceeds

Use of Proceeds 79 Dividend Policy 81 Capitalization 82

Managements Discussion and Analysis of Financial Condition and Results of Operations

Managements Discussion and Analysis of Financial Condition and Results of Operations 87

Business

Business 101 Management 165 Executive and Director Compensation 175 Certain Relationships and Related Person Transactions 193 Principal Stockholders 196

Description of Capital Stock

Description of Capital Stock 199 Shares Eligible For Future Sale 205 Material United States Federal Income Tax Consequences to Non-U.S. Holders 208

Underwriting

Underwriting 213 Legal Matters 220 Experts 220 Where You Can Find More Information 220 Index to Financial Statements F-1 Through and including , 2024 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to, the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summar

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing